Blink Charging Stock Climbs After Better-Than-Expected Q1 Results
Blink Charging reported quarterly losses of 13 cents per share which beat the analyst consensus estimate of losses of 24 cents by 45.83%.
Duolingo Shares Dive After Q1 Results: What’s Going On?
Duolingo shares traded lower Thursday afternoon after the company reported first-quarter financial results.
Toncoin Up More Than 8% In 24 hours
Over the past 24 hours, Toncoin's (CRYPTO: TON) price rose 8.79% to $6.32. This continues its positive trend over the past week where it has experienced a 21.0% gain, moving from $5.13 to its current price. As it stands right now, the coin's all-time high is $7.63.
Analysts’ Varied Perspectives On CytomX’s CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer
Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.
What’s Going On With Peloton’s Stock?
Peloton shares soared following a CNBC report Tuesday which said multiple private equity firms are considering a buyout of the company. According to the report, the company has discussed plans to go private with at least one firm and multiple private equity firms have expressed interest.
What’s Going On With Upstart Stock?
Upstart Holdings shares are trading higher Thursday. The stock is rebounding after falling following the company's first-quarter financial report on Tuesday. Upstart reported a quarterly loss of 31 cents per share which beat the analyst consensus estimate of a loss of 39 cents. The company also beat analysts' expectations with quarterly sales of $128 million, representing a 24.36% increase in sales from the same period last year.
Bumble Shares Soar On Q1 Earnings Beat: The Details
Bumble reported impressive first-quarter 2024 results, outperforming expectations across key metrics. The company posted EPS of 19 cents, surpassing estimates of 7 cents by 171.43%, while sales of $267.77 million exceeded expectations of $242.9 million by 0.87%.
What’s Going On With G1 Therapeutics Stock?
According to a report, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics. According to the report, one offer from TerSera is rumored to have a contingent value right which could value the company at between $12 and $14 per share.
Change Healthcare Cyberattack: GoodRx Expects Low Single Digit Million-Dollar Impact In 2024
GoodRx's Q1 earnings: $0.08 EPS, sales hit $197.88 million, beating expectations fueled by prescription transactions and pharma solutions. Q2 forecast: ~$200 million revenue, optimistic 2024 outlook.
Weak Sales From Lipitor, Norvasc Hurt Viatris’ Q1 Earnings, Lowers Annual Forecast
Viatris reports Q1 EPS in line with consensus at $0.67, with sales slightly missing expectations at $3.66 billion. Strong growth in Emerging Markets and Europe offset by challenges in North America. Guidance adjusted slightly downward for 2024.